BiotechTube
Home/Pipeline/Additional Carrier Program 2

Additional Carrier Program 2

Not specified

Pre-clinicalActive

Key Facts

Indication
Not specified
Phase
Pre-clinical
Status
Active
Company
Ten Boron

About Ten Boron

Tenboron is a Finnish biotech pioneering next-generation carriers for Boron Neutron Capture Therapy (BNCT), a targeted radiotherapy. The company is advancing a clinical-stage pipeline led by TB0010, an antibody-boron conjugate for recurrent head and neck cancer, with Phase 1b trials on the horizon. Founded in 2010, it leverages a seasoned leadership team with deep experience in oncology drug development and BNCT. Tenboron operates as a private, pre-revenue entity, relying on partnerships for manufacturing and clinical research.

View full company profile

Therapeutic Areas

Oncology

Other Not specified Drugs

DrugCompanyPhase
Inflammation ProgramsArcus BiosciencesNot Specified
Bone Marrow Conditioning ProgramTelix PharmaceuticalsPipeline
AGMB-447Agomab TherapeuticsNot Disclosed
AGMB-101Agomab TherapeuticsNot Disclosed
TRIFERTY-ATM®Laboratorio Reig JofreApproved/Commercial
AGEN1571 (anti-ILT2)AgenusNot specified
AGEN1777AgenusNot specified
AGEN1721AgenusNot specified
INCAGN1876 (GITR Agonist)AgenusNot specified
INCAGN1949 (OX40 Agonist)AgenusNot specified
AGEN1327 (anti-TIGIT)AgenusNot specified
AGEN2373 (CD137 Agonist)AgenusNot specified